An open label, randomized, 2-sequence, multiple-dose, cross-over study to investigate the drug-drug interaction of Sevikar and Crestor in healthy adult volunteers
Phase of Trial: Phase I
Latest Information Update: 18 Sep 2019
Price : $35 *
At a glance
- Drugs Olmesartan medoxomil/amlodipine (Primary) ; Rosuvastatin (Primary)
- Indications Atherosclerosis; Cardiovascular disorders; Hypercholesterolaemia; Hyperlipidaemia; Hypertension; Hypertriglyceridaemia
- Focus Pharmacokinetics
- Sponsors Daewoong Pharmaceutical
- 28 Apr 2015 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
- 20 Jun 2014 New source identified and integrated (Clinical Research Information Service (CriS) - Republic of Korea: KCT0001058).
- 25 Mar 2014 New trial record